Pfizer and Valneva Lyme Disease Vaccine Shows 73% Efficacy in Phase 3 Trial

Pfizer and Valneva's Lyme disease vaccine candidate demonstrated 70-73% efficacy in a Phase 3 clinical trial, positioning it as a potential first-in-class preventive treatment. Lyme disease affects an estimated 476,000 Americans annually and is expanding its geographic range due to climate-driven tick migration. If approved, it would be the only Lyme disease vaccine available; a previous Lyme vaccine was withdrawn from the market in 2002 due to low demand. The results are particularly relevant for readers in the Midwest and Northeast US where tick-borne diseases are prevalent.